Daewoong Pharmaceutical challenges to make KRW 500 billion sales per a year in the Chinese market

Daewoong Pharmaceutical has made an ambitious plan to reach KRW 500 billion sales by 2020 in the Chinese market.

According to Daewoong Pharmaceutical, starting with the launch of ‘Ursa’in 2012, the companies have established the troika lineup with other successful launches of ‘Bearse’ and ‘Newlanta’ in China.

First and foremost, its main product, Ursa,is running marketing based on its technol...